

# Reply to Letter to the Editor Regarding: “Myocarditis and Cardiac Complications Associated With COVID-19 and mRNA Vaccination”



## Keywords

COVID • Myocarditis

To the Editor,

We thank Lampejo and Durkin for their interest in our recent publication, Myocarditis and Cardiac Complications Associated With COVID-19 and mRNA Vaccination: A Pragmatic Narrative Review to Guide Clinical Practice [1], and for their letter regarding the use of non-steroidal anti-inflammatory drugs (NSAIDs) in these clinical settings.

The management of COVID-19 and the complications of specific organ involvement is a rapidly expanding area of medicine, and there are limited data on the treatment of COVID-19 and mRNA vaccination-related myocarditis. In general, the use of NSAIDs in myocarditis is not recommended [2], based on experimental data from seminal animal studies indicating possible harm in viral aetiologies of myocarditis. Furthermore, NSAIDs are generally discouraged in acute or chronic cases of heart failure [3]. Though widely used in cases of isolated pericarditis, human safety data of NSAIDs in myocarditis and myopericarditis is limited to small retrospective audits [4,5], and robust data related specifically to COVID-19 is absent. Importantly, NSAIDs remain first-line therapy in pericarditis [6]. However, we agree with Lampejo and Durkin that, consistent with guideline recommendations for myocarditis and pericarditis [2,6], the use of NSAIDs should be carefully considered in cases related to COVID-19 or presentation associated with mRNA vaccination.

David J. Holland, MBBS, PhD\*

Tony Stanton, MBChB, PhD

Cardiology Department, Sunshine Coast University Hospital,  
Sunshine Coast, Qld, Australia

\*Corresponding author at: Cardiology Department, Sunshine Coast University Hospital, Birtinya, Qld, 4575, Australia.

Email: [d.holland@uq.edu.au](mailto:d.holland@uq.edu.au)

## References

- [1] Holland DJ, Blazak PL, Martin J, Broom J, Poulter RS, Stanton T. Myocarditis and cardiac complications associated with COVID-19 and mRNA vaccination: a pragmatic narrative review to guide clinical practice. *Heart Lung Circ.* 2022;31(7):924–33.
- [2] Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J.* 2013;34(33):2636–48. 48a-48d.
- [3] Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, MacDonald PS, Hopper I, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018. *Heart Lung Circ.* 2018;27(10):1123–208.
- [4] Mirna M, Schmutzler L, Topf A, Boxhammer E, Sipos B, Hoppe UC, et al. Treatment with non-steroidal anti-inflammatory drugs (NSAIDs) does not affect outcome in patients with acute myocarditis or myopericarditis. *J Cardiovasc Dev Dis.* 2022;9(2):32.
- [5] Berg J, Lovrinovic M, Baltensperger N, Kissel CK, Kottwitz J, Manka R, et al. Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical follow-up. *Open Heart.* 2019;6(1):e000990.
- [6] Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: the Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). *Eur Heart J.* 2015;36(42):2921–64.